Shanghai, China, and Lexington, MA., - September 27, 2023 - NeuShen Therapeutics (the “Company”), a global biotechnology company dedicated to developing innovative treatments for neurological and psychiatric disorders with a dual-platform strategy consisting of small molecule discovery and AAV-based gene therapy, today announced that a poster featuring the Company’s groundbreaking selective M4 receptor positive allosteric modulator (PAM) will be presented at the Society for Neuroscience’s annual meeting “Neuroscience 2023”, which takes place during November 11-15 in Washington, D.C.

This represents another significant milestone attained by the Company following its presentation of the novel KCNQ2/3 selective activator NS-041 at the 2023 American Chemical Society (ACS) Fall Meeting in August. The company remains committed to the advancement of therapies for neurological and psychiatric disorders, with the goal of delivering safe and effective treatments to patients as early as possible.

Schizophrenia is a serious mental disorder that affects approximately one in every hundred people. Current treatment methods are relatively effective for positive symptoms, such as hallucinations and delusions, but no drugs have been approved for treating negative symptoms, such as social withdrawal, apathy, and cognitive impairment. At the same time, some side effects associated with current treatment also limit their clinical use.

Extensive research has shown that modulating muscarinic acetylcholine receptors could have the potential to treat negative symptoms and cognitive impairment associated with schizophrenia. Several candidates are currently undergoing clinical studies.

NeuShen’s candidate is a novel selective M4 receptor positive allosteric modulator with good in vitro potency. This candidate has shown potential for the treatment of both positive and negative symptoms of schizophrenia preclinically. In addition to its efficacy, the safety profile is also favorable. Overall, this candidate has demonstrated best-in-class potential and is currently undergoing further profiling. It will soon proceed to the development stage. More details will be presented at the conference.

Presentation Details:

Presentation Title: A Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

Presenting Author: Dr. Lingyun Wu, Senior Vice President of Discovery Chemistry, NeuShen Therapeutics

Session Number: PSTR242

Session Title: Biomarkers of Affective Disorders and Schizophrenia

Location: Walter E. Washington Convention Center, Washington, D.C.

Date & Time: November 13, 2023, 8:00 am – 12:00 pm EST

About NeuShen Therapeutics

NeuShen Therapeutics is a global biotechnology company focused on innovative drug research and development to address neurological and psychiatric disorders, using a dual-platform strategy consisting of small molecule discovery and AAV-based gene therapy. With operations in Shanghai, China and Lexington, MA., NeuShen boasts a world-class R&D team in CNS field and is honored to be advised by an outstanding board of directors and scientific advisory board.